Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Biosantech initiates phase I/II trial of synthetic AIDS vaccine Tat Oyi

March 5, 2013

ViiV Healthcare grants voluntary license to increase access to HIV medicine for children

March 1, 2013

FDA grants priority review to dolutegravir NDA

Feb. 18, 2013

Tricyclic pim kinase inhibitors reported by the Spanish CNIO

Feb. 4, 2013

FAK inhibitors described at Merck & Co.

Feb. 4, 2013

New anti-properdin antibodies developed at the University of Pennsylvania

Feb. 1, 2013

Shionogi & Co. presents novel agents for HIV

Jan. 30, 2013

New agents for HIV infection presented by Gilead Sciences

Jan. 28, 2013

Gilead initiates phase III program for tenofovir alafenamide in HIV

Jan. 25, 2013

European approval for new 800-mg tablet of Prezista

Jan. 16, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...